Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).
about
Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic ReviewDiabetes impairs hematopoietic stem cell mobilization by altering niche function.Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.EPIC: an effective low toxicity regimen for relapsing lymphoma.Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomasCombination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphomaPhase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin's lymphoma patients with a poor performance status or comorbidity.Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology ConsortiumSalvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab eraDegenerative effect of Cisplatin on testicular germinal epitheliumPrognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy.Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphomaNon-Hodgkin's lymphoma. II: Management problemsFludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removalCell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patientsEffects of nitric oxide (NO) synthesis inhibition on antitumor responses during interleukin-2 (IL-2) treatment of mice.Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma.Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemiaCladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignanciesBaseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapyPhase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaHistological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal typeEvaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-HSalvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.Intracranial primary dural diffuse large B-cell lymphoma successfully treated with chemotherapy.Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma.Mobilization and collection of CD34(+) cells for autologous transplantation of peripheral blood hematopoietic progenitor cells in children: analysis of two different granulocyte-colony stimulating factor doses.A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
P2860
Q28554530-5CF4D7EC-55CC-4ABD-B89F-5F112EE40B7FQ30543776-6B334EAD-BF9D-43CB-BC9A-13EC096768F4Q33365711-0AD427C7-D4D6-4C94-96E7-895D8C8842DAQ33372841-E5CEFDA8-7E06-480C-8206-A0763A897F14Q33383571-0C435BF5-E601-4143-B744-302446F6D2E9Q33383608-9DB8804A-1AC0-4A9C-A0CC-075AB817D96CQ33493801-58360766-3976-419C-8414-1FA2D1E44E57Q33728214-EEBFDB3B-208F-4F83-A2FF-15CF65D6707DQ33817711-A2215EAD-BF7A-4BF8-841F-ABC36BB54BF7Q34064220-5B5DFE72-FBF3-41BB-892C-0AEE9F39EFFBQ34269186-EE51CA3B-296A-4969-85B7-422DAD1A0080Q34293322-5A94AC4B-45A4-41C3-9DA8-0BDFA7DEE4E0Q34477705-2C0CBD9C-D441-4D33-930C-171C4E8EA1A2Q34621900-B4BCD250-6804-4490-96FE-81338994C491Q35061617-133CC152-54EC-4729-91A2-3B5DA4D529F7Q35218039-710625B7-CE6E-4900-BE7D-7D7BAE254E67Q35249315-958F8603-5CCA-4CF8-9589-5A390B3DC2EAQ35822306-6219AD0D-96F6-4D5D-96C6-D2922ECEB64CQ35848805-3BC5A640-02C2-4007-AA4F-2EFA4EFDE900Q35915899-3E103D07-286A-4F6B-9DBC-AE6ADCDFB18DQ35920657-CE66373F-F868-47FE-A228-6680353B3821Q35936994-455A0BC6-AA31-4264-913B-C8AF5003C903Q35938791-665B8949-8DCD-4B86-A009-172C5088CEADQ35986409-1B4226B7-5DA5-40BA-8B3B-38E645CC3B67Q36118111-08DA8151-5F58-472A-8B89-F68E3EC3AF88Q36617540-2525F21F-55DF-43B9-8F09-803F5014AD2DQ36648720-85C2B5E2-5ACD-49D3-BD39-4B951A6E6B61Q36700470-AD742B91-29C5-4BAC-B2BA-DD0E610453D1Q36822155-5749BC7C-41A0-408F-8D61-4C476D4268AEQ37108162-57AEEC53-F9C3-41AA-968E-2CCB2457CB70Q37136655-15385537-0C5D-488A-A1BF-53ABFB4E0ADCQ37526899-A675725B-FA05-4F56-B532-B50E4B087CF7Q37597479-2866F6CE-FBEF-489C-BD31-F8B8B5815D78Q37713596-644BD63E-93CB-4104-94E3-F6FA08C6C223Q42585846-B54EED83-B003-4285-8681-99600E6760D3Q50042735-5FDADD9E-86C7-4AE0-A556-19BDFC8418D4
P2860
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Effective salvage therapy for ...... ra-C and dexamethasone (DHAP).
@en
Effective salvage therapy for ...... h-dose Ara-C and dexamethasone
@nl
type
label
Effective salvage therapy for ...... ra-C and dexamethasone (DHAP).
@en
Effective salvage therapy for ...... h-dose Ara-C and dexamethasone
@nl
prefLabel
Effective salvage therapy for ...... ra-C and dexamethasone (DHAP).
@en
Effective salvage therapy for ...... h-dose Ara-C and dexamethasone
@nl
P2093
P1433
P1476
Effective salvage therapy for ...... Ara-C and dexamethasone (DHAP)
@en
P2093
Cabanillas F
Hagemeister FB
Jagannath S
McLaughlin P
Salvador P
Velasquez WS
P304
P407
P577
1988-01-01T00:00:00Z